The Phase 3 trial investigating Survodutide (BI 456906) for people living with overweight or obesity without diabetes reached its primary completion on 2025-12-02. This study, which enrolled 726 participants, aims to assess the drug's efficacy in weight loss.
Background
Survodutide is being investigated for its potential in managing overweight and obesity. The target population for this specific trial includes adults with a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more and at least one weight-related health problem. Importantly, the study excludes individuals with type 2 diabetes and those who have previously not managed to lose weight by changing their diet.
Trial design
This completed trial, identified as NCT06066515, is a Phase 3 study designed to evaluate Survodutide. It enrolled 726 adult participants living with Obesity. Participants were randomly divided into groups to receive either Survodutide or a placebo. The study specifically targeted individuals who do not have diabetes and have previously not managed to lose weight through diet changes.
What this means
The primary completion of this Phase 3 trial indicates that all data collection for the main objectives has concluded. Researchers will now proceed with data analysis to determine whether Survodutide helps people living with overweight or obesity without diabetes to lose weight. The findings from this study are anticipated to provide crucial insights into the drug's potential role in obesity management.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06066515, titled "A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight," was updated with primary completion on 2025-12-02 on clinicaltrials.gov.